3) and an improvement in quality of life.40 Pending the results of cardiovascular safety studies in obesity (SURMOUNT MMO) and diabetes (SURPASS-CVOT), TZP has demonstrated in the SURMOUNT-1 trial a reduction in the predicted 10-year cardiovascular risk in patients with obesity and an initially moderate-to-high risk of cardiovascular disease.43 TZP treatment effectively reduces the apnoeahypopnoea index by up to 23 events per hour, as well as blood pressure, C-reactive protein, and symptoms related to poor sleep quality (as assessed by PROMIS Sleep scales), likely due to weight loss and improvement in adipocyte dysfunction.44 Moreover, TZP induces remission of histologically confirmed metabolic dysfunction-associated steatohepatitis (MASH) in a dose-dependent manner (4462% of cases, depending on the dose) and leads to improvement of at least one stage of liver fibrosis in 5155% of caseshigher than that observed with placebo45 (Fig

It is also, based on what I have been able to find, very unlikely to be working
For example, a person with OCD can be obsessed with germs and cleanliness, and wash their hands repeatedly until they feel a sense of relief from their anxiety
CagriSema and Amycretin work on the GLP-1 and amylin receptors, Retrarutide on GLP-1, GIP and glucagon, Survodutide, Mazdutide, Pemvidutide and Efinopegdutide on GLP-1 and glucagon and still more are coming
Any UK prescriber considering its use must be aware that it would be supplied as an imported unlicensed medicine on a named-patient basis, with full prescriber responsibility